2023 World Conference on Lung Cancer (Posters)-EP11.03. Long-term Outcomes and Toxicity in Patients with Metastatic Non Small Cell Lung Cancer Treated with Immunotherapy Containing Regimens

EP11.03. Long-term Outcomes and Toxicity in Patients with Metastatic Non Small Cell Lung Cancer Treated with Immunotherapy Containing Regimens - PDF(Slides)

Back to course

Pdf Summary

This study aimed to examine the long-term outcomes and toxicities in patients with metastatic non-small cell lung cancer (mNSCLC) treated with immunotherapy-containing regimens. The study was a retrospective observational study conducted across the Western Sydney Local Health District from January 2014 to December 2020.<br /><br />The inclusion criteria for the study were mNSCLC patients treated with first- or second-line immunotherapy or combination chemotherapy-immunotherapy. The study assessed the rate of progression (PD), progression-free survival (PFS), overall survival (OS), and safety endpoints, stratified by PDL-1 expression and treatment completion.<br /><br />The results showed that long-term responders had a good ECOG performance status and high PDL-1 expressing tumors with adenocarcinoma histopathology. The PFS and OS rates were high, and although one-third of patients progressed, the majority were salvaged with subsequent therapy.<br /><br />The study found that survival outcomes were unaffected by premature treatment cessation, suggesting a durable response to immunotherapy. However, almost half of the patients experienced long-term toxicities, with endocrinopathies being the most common.<br /><br />The features of progression in patients included oligo-progression as the most common type, with lung or pleural disease being the predominant sites. The rate of PD was 31% with a median follow-up of 39 months.<br /><br />The study also assessed subsequent management strategies for progression, with local therapy only, local and systemic therapy, systemic therapy, and best supportive care being the main approaches.<br /><br />In conclusion, this study highlights the favorable long-term outcomes and manageable toxicities in patients with mNSCLC treated with immunotherapy-containing regimens. The findings suggest that immunotherapy can provide durable responses in this patient population. However, close monitoring of long-term toxicities is important for optimal patient management.

Asset Subtitle

Meghana Maddula

Meta Tag

Speaker Meghana Maddula

Topic Metastatic NSCLC: Immunotherapy - Retrospective

Keywords

metastatic non-small cell lung cancer

immunotherapy-containing regimens

long-term outcomes

toxicities

retrospective observational study

PDL-1 expression

progression-free survival

overall survival

ECOG performance status

endocrinopathies